Data show clear evidence of anti-tumor activity and durable partial and complete responses in heavily pre-treated patients with tumors that progressed through checkpoint inhibitors AU-007’s unique ...
Bioscience, an immuno-oncology company working to revolutionize cancer care through development of its lead immune-activating antibody therapeutic imneskibart (AU-007), today announced that new Phase ...
Add Yahoo as a preferred source to see more of our stories on Google. Aulos Bioscience plans to progress its lead IL-2-targeting asset Aulos Bioscience’s cancer therapy, imneskibart, could enter a ...
US-based immuno-oncology company Aulos Bioscience has announced the first patients have been dosed as part of a trial investigating avelumab, marketed as Bavencio by its original developer Merck KgaA ...
ATP and Biolojic Design have teamed up to create IL-2-focused cancer biotech Aulos Bioscience. The startup begins life with IL-2-binding monoclonal antibodies designed by Biolojic Design and a $40 ...
Phase 2 data presented at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting show deep and durable tumor regressions in heavily pre-treated melanoma patients, with a mild safety ...
Aulos(TM) Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, today announced the presentation of new data ...
The poster will be presented in the Exhibit Hall at McCormick Place. An electronic version will also be available on the ASCO 2026 online meeting platform. Imneskibart (AU-007) is a human IgG1 ...
Aulos Bioscience’s cancer therapy, imneskibart, could enter a registrational study either in melanoma, non-small cell lung cancer (NSCLC) or both, as soon as 2026. Speaking to Clinical Trials Arena, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results